Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPT NASDAQ:BLUE NASDAQ:CBPO NASDAQ:ONCE NASDAQ:XLRN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$12.77-1.1%$11.99$3.98▼$13.68$1.96B1.932.01 million shs847,336 shsBLUEbluebird bio$4.97$4.78$3.20▼$25.10$48.67M0.27452,966 shsN/ACBPOChina Biologic Products$119.99$119.23$99.74▼$120.05$4.72B0.47148,695 shs390,921 shsONCESpark Therapeutics$0.18$113.43$34.53▼$114.20$6.94M2.05891,560 shsN/AXLRNAcceleron Pharma$178.75$176.25$108.82▼$189.99$10.93B0.13572,759 shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies-1.30%+2.38%-1.00%+23.30%+181.26%BLUEbluebird bio0.00%0.00%0.00%0.00%-56.98%CBPOChina Biologic Products0.00%0.00%0.00%0.00%0.00%ONCESpark Therapeutics0.00%0.00%0.00%0.00%0.00%XLRNAcceleron Pharma0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$12.77-1.1%$11.99$3.98▼$13.68$1.96B1.932.01 million shs847,336 shsBLUEbluebird bio$4.97$4.78$3.20▼$25.10$48.67M0.27452,966 shsN/ACBPOChina Biologic Products$119.99$119.23$99.74▼$120.05$4.72B0.47148,695 shs390,921 shsONCESpark Therapeutics$0.18$113.43$34.53▼$114.20$6.94M2.05891,560 shsN/AXLRNAcceleron Pharma$178.75$176.25$108.82▼$189.99$10.93B0.13572,759 shsN/A The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies-1.30%+2.38%-1.00%+23.30%+181.26%BLUEbluebird bio0.00%0.00%0.00%0.00%-56.98%CBPOChina Biologic Products0.00%0.00%0.00%0.00%0.00%ONCESpark Therapeutics0.00%0.00%0.00%0.00%0.00%XLRNAcceleron Pharma0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.88Moderate Buy$12.38-5.57% DownsideBLUEbluebird bio 2.17Hold$25.75418.11% UpsideCBPOChina Biologic Products 0.00N/AN/AN/AONCESpark Therapeutics 0.00N/AN/AN/AXLRNAcceleron Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CBPO, BLUE, ONCE, ADPT, and XLRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/6/2025ADPTAdaptive BiotechnologiesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$10.00 ➝ $14.008/6/2025ADPTAdaptive BiotechnologiesTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $15.008/6/2025ADPTAdaptive BiotechnologiesPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$13.00 ➝ $15.006/18/2025ADPTAdaptive BiotechnologiesCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$15.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$178.96M11.15N/AN/A$1.37 per share9.57BLUEbluebird bio$103.95M0.47N/AN/A$35.59 per share0.14CBPOChina Biologic Products$503.70M9.38$5.01 per share23.93$45.09 per share2.66ONCESpark Therapeutics$64.72M0.11N/AN/A$13.15 per share0.01XLRNAcceleron Pharma$92.52M118.15N/AN/A$11.74 per share15.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$159.49M-$0.82N/AN/AN/A-59.07%-60.93%-23.03%11/6/2025 (Estimated)BLUEbluebird bio-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%N/ACBPOChina Biologic Products$138.81M$4.2833.5227.90N/A27.43%8.32%7.64%N/AONCESpark Therapeutics-$78.82M-$2.11N/AN/AN/A-358.41%-59.10%-33.13%N/AXLRNAcceleron Pharma-$166.03M-$4.21N/AN/AN/A-226.01%-32.11%-29.45%N/ALatest CBPO, BLUE, ONCE, ADPT, and XLRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025ADPTAdaptive Biotechnologies-$0.24-$0.17+$0.07-$0.17$49.40 million$49.94 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/ABLUEbluebird bioN/AN/AN/AN/AN/ACBPOChina Biologic ProductsN/AN/AN/AN/AN/AONCESpark TherapeuticsN/AN/AN/AN/AN/AXLRNAcceleron PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A2.842.75BLUEbluebird bio0.370.510.33CBPOChina Biologic ProductsN/A12.0110.13ONCESpark Therapeutics0.354.674.35XLRNAcceleron PharmaN/A12.1412.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%BLUEbluebird bio87.43%CBPOChina Biologic Products34.77%ONCESpark Therapeutics88.37%XLRNAcceleron Pharma90.35%Insider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies6.40%BLUEbluebird bio1.40%CBPOChina Biologic Products2.73%ONCESpark Therapeutics6.00%XLRNAcceleron Pharma1.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790152.27 million142.53 millionOptionableBLUEbluebird bio5209.79 million9.59 millionOptionableCBPOChina Biologic Products2,26939.36 millionN/AOptionableONCESpark Therapeutics36838.52 millionN/ANo DataXLRNAcceleron Pharma31261.16 million60.12 millionOptionableCBPO, BLUE, ONCE, ADPT, and XLRN HeadlinesRecent News About These CompaniesAcceleron P Stock Price Today | NASDAQ: XLRN Live - Investing.comJune 28, 2025 | investing.comUK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma DealJanuary 2, 2025 | benzinga.comAcceleron advances cold fusion technologyDecember 17, 2024 | neimagazine.comNAcceleron Banks on Muons for Colder FusionDecember 6, 2024 | msn.comMerck preps filings after blockbuster-in-waiting Winrevair succeeds in severe PAH studyNovember 26, 2024 | fiercepharma.comFAcceleron attracts turbocharged demand for debut SwissieOctober 17, 2024 | globalcapital.comGAcceleron Fusion has raised $15M to take a stab at colder fusion, filing revealsOctober 5, 2024 | techcrunch.comTAcceleron Fusion has raised $15M to take another stab at cold fusion, filing revealsOctober 1, 2024 | yahoo.comMerck confirms $11.5bn Acceleron takeover dealAugust 6, 2024 | pharmaphorum.comPEarnings to Watch Next Week: ON Semiconductor, Ferrari, General Motors and Moderna in FocusApril 26, 2024 | fxempire.comFBig Pharma Q1 earnings roundup: AstraZeneca, BMS, Merck, SanofiApril 26, 2024 | mmm-online.comMORBIMED CAPITAL GP II LLC's Net WorthFebruary 27, 2024 | benzinga.comXLRN Historical DataOctober 20, 2023 | investing.comMSD eyes March FDA decision on PAH drug sotaterceptOctober 15, 2023 | pharmaphorum.comPBrexit Bargain Buys: 14 More Stocks Picked by Morgan StanleyApril 15, 2023 | thestreet.comAstellas Pharma IncMarch 17, 2023 | reuters.comHempStreet partners with MGC Pharma launches ArtemiCJanuary 30, 2023 | health.economictimes.indiatimes.comAcceleron Corp Becomes a Digital Correspondent BankDecember 14, 2022 | finance.yahoo.comPharma Contract Sales Market Report 2022-2032November 30, 2022 | finance.yahoo.comMerck to buy Imago for $1.35 bln to broaden portfolio of blood disorder drugsNovember 21, 2022 | reuters.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesEyes on the Sky: AST SpaceMobile Prepares for Commercial LaunchBy Jordan Chussler | September 8, 20253 Tariff-Proof Retailers Making New All-time HighsBy Dan Schmidt | September 1, 2025Low-Cost Global Exposure: 3 Diversified ETFs for Value InvestorsBy Nathan Reiff | September 2, 2025Palantir Insider Selling: Risk Signal or Normal Activity?By Chris Markoch | September 4, 2025Best Bang For Your Buck? 2 Bargain Stocks with 30%+ UpsideBy Nathan Reiff | September 14, 2025CBPO, BLUE, ONCE, ADPT, and XLRN Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$12.77 -0.14 (-1.08%) As of 02:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.bluebird bio NASDAQ:BLUEbluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.China Biologic Products NASDAQ:CBPOChina Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.Spark Therapeutics NASDAQ:ONCESpark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.Acceleron Pharma NASDAQ:XLRNAcceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case This Defense Stock Is Up 113% This Year—Is It Still a Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
